Results 1 to 10 of about 45,591 (119)

Protective Effects of Adenosine Triphosphate and Flunarizine on Erlotinib-Induced Ovarian Damage: An Experimental Study [PDF]

Life
(1) Background: Erlotinib is a tyrosine kinase inhibitor (TKI) widely used in cancer therapy; however, its potential adverse effects on ovarian tissue have not been fully elucidated. The present study aimed to investigate erlotinib-induced ovarian injury
Arzu Yavuz, Kemine Uzel, Esra Tuba Sezgin, Mehmet Kuzucu, Nesrin Yılmaz, Gülcenaz Yazici, Engin Hendem, Halis Süleyman   +7 more
doaj   +2 more sources

PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs

Cells, 2021
Tyrosine kinase inhibitors (TKIs) targeting the kinase domain of the epidermal growth factor receptor (EGFR), such as erlotinib, have dramatically improved clinical outcomes of patients with EGFR-driven non-small cell lung carcinomas (NSCLCs).
Nadiia Lypova, Susan M. Dougherty, Lilibeth Lanceta, Jason Chesney, Yoannis Imbert-Fernandez   +4 more
doaj   +1 more source

Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway

Frontiers in Oncology, 2021
BackgroundErlotinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, demonstrated therapeutic efficacy against pancreatic cancer.
Huiting Xu, Runzhi Chen, Qian Shen, Dongmei Yang, Hui Peng, Jin Tong, Qiang Fu   +6 more
doaj   +1 more source

Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan

Current Research in Toxicology, 2021
Objective: To evaluate drug-drug interactions (DDIs) between gefitinib or erlotinib with fluoxetine, and/or losartan. Methods: Human pooled microsomes, supersomes, and cryopreserved human hepatocytes were used to monitor DDIs in vitro.
Thu-Lan T. Luong, Michael J. McAnulty, David L. Evers, Brian J. Reinhardt, Peter J. Weina   +4 more
doaj   +1 more source

Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study

Thoracic Cancer, 2022
Background In the phase II JO25567 study (JapicCTI‐111390), erlotinib plus bevacizumab demonstrated a significant clinical benefit in Japanese patients with epidermal growth factor receptor mutation‐positive (EGFR+) non‐small cell lung cancer (NSCLC ...
Yukio Hosomi, Takashi Seto, Makoto Nishio, Koichi Goto, Noboru Yamamoto, Isamu Okamoto, Kosei Tajima, Yusuke Kajihara, Nobuyuki Yamamoto   +8 more
doaj   +1 more source

Genome‐scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinib‐resistant lung cancer

Molecular Oncology, 2021
Erlotinib is highly effective in lung cancer patients with epidermal growth factor receptor (EGFR) mutations. However, despite initial favorable responses, most patients rapidly develop resistance to erlotinib soon after the initial treatment. This study
Jieun Lee, Ahyoung Choi, Sung‐Yup Cho, Yukyung Jun, Deukchae Na, Ahra Lee, Giyong Jang, Jee Young Kwon, Jaesang Kim, Sanghyuk Lee, Charles Lee   +10 more
doaj   +1 more source

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis

Diseases, 2023
The objective of this systematic review and meta-analysis was to assess and contrast the efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the treatment of patients with advanced non-small cell lung cancer (NSCLC).
Prashant Sakharkar, Sonali Kurup
doaj   +1 more source

BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C‐MYC/PLCG1/Perk Axis

Advanced Science, 2023
Erlotinib, an EGFR tyrosine kinase inhibitor, is used for treating patients with cancer exhibiting EGFR overexpression or mutation. However, the response rate of erlotinib is low among patients with gastric cancer (GC).
Fangyuan Li, Junxian Yu, Tao Pan, Haoran Feng, Jianfang Li, Beiqin Yu, Zhiyuan Fan, Qingqing Sang, Mengdi Chen, Mingde Zang, Junyi Hou, Xiongyan Wu, Yingyan Yu, Yuan‐Yuan Li, Chao Yan, Zhenggang Zhu, Liping Su, Bingya Liu   +17 more
doaj   +1 more source

Quantitative determination of erlotinib in human serum using competitive enzyme-linked immunosorbent assay

Journal of Pharmaceutical Analysis, 2018
A selective and sensitive competitive enzyme-linked immunosorbent assay (ELISA) method was developed and validated for the quantification of erlotinib in 50 µL of samples of human serum.
Yuta Yamamoto, Tetsuya Saita, Yutaro Yamamoto, Masashi Shin   +3 more
doaj   +1 more source

Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer

Scientific Reports, 2022
The goals of this study were to identify transcriptomic changes that arise in basal-like breast cancer cells during the development of resistance to epidermal growth factor receptor inhibitors (EGFRi) and to identify drugs that are cytotoxic once EGFRi ...
Narmeen S. Rashid, David C. Boyd, Amy L. Olex, Jacqueline M. Grible, Alex K. Duong, Mohammad A. Alzubi, Julia E. Altman, Tess J. Leftwich, Aaron D. Valentine, Nicole S. Hairr, Emily K. Zboril, Timothy M. Smith, Adam D. Pfefferle, Mikhail G. Dozmorov, J. Chuck Harrell   +14 more
doaj   +1 more source